HF
IMDX

HRT Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

HRT Financial’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,149
Closed -$31K – 3286
2025
Q1 		$31K Buy
+10,149
New +$27.4K ﹤0.01% 2269
2023
Q3 		– Sell
-1,366
Closed -$6K – 2889
2023
Q2 		$6K Buy
+1,366
New +$6.88K ﹤0.01% 2215
2022
Q3 		– Sell
-697
Closed -$12K – 3296
2022
Q2 		$12K Buy
+697
New +$15.8K ﹤0.01% 2656

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial's IMDX Position: Q2 2025 in Review

HRT Financial sold out of Insight Molecular Diagnostics (IMDX) in Q2 2025, closing a stake of 10,149 shares — an estimated $31K sold.

HRT Financial first reported a position in IMDX in Q2 2022 and held it in 3 quarters. The position peaked at $31K in Q1 2025. 30 funds tracked by Wall St. Rank hold IMDX as of Q2 2025.

  • HRT Financial reported no remaining Insight Molecular Diagnostics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 10,149 Insight Molecular Diagnostics shares in Q2 2025, an estimated $31K.
  • HRT Financial first reported a position in Insight Molecular Diagnostics in Q2 2022 and held it in 3 quarters.
  • HRT Financial's Insight Molecular Diagnostics position peaked at $31K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.